SMMT

Summit Therapeutics Inc. Common Stock

15.38

USD

SMMT Earnings Reports

Positive Surprise Ratio

SMMT beat 3 of 13 last estimates.

23%

Next Report

Date of Next Report

Feb 23, 2026

Estimate for Q4 25 (Revenue/ EPS)

$102.00M

-$0.06

Implied change from Q3 25 (Revenue/ EPS)

-80.65%

Implied change from Q4 24 (Revenue/ EPS)

-25.00%

Summit Therapeutics Inc. Common Stock earnings per share and revenue

On Oct 20, 2025, SMMT reported earnings of -0.31 USD per share (EPS) for Q3 25, missing the estimate of -0.13 USD, resulting in a -130.48% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -4.55% price change (close before vs. close after earnings).

Looking ahead to Q4 25, 19 analysts forecast an EPS of -0.06 USD, with revenue projected to reach 102.00 million USD, implying an decrease of -80.65% EPS, and -- of --% in Revenue from the last quarter.

FAQ

What were Summit Therapeutics Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?

For Q3 2025, Summit Therapeutics Inc. Common Stock reported EPS of -$0.31, missing estimates by -130.48%, and revenue of $0.00, 0% as expectations.

How did the market react to Summit Therapeutics Inc. Common Stock's Q3 2025 earnings?

The stock price moved down -4.55%, changed from $20.99 before the earnings release to $20.04 the day after.

When is Summit Therapeutics Inc. Common Stock expected to report next?

The next earning report is scheduled for Feb 23, 2026.

What are the forecasts for Summit Therapeutics Inc. Common Stock's next earnings report?

Based on 19 analysts, Summit Therapeutics Inc. Common Stock is expected to report EPS of -$0.06 and revenue of $102.00M for Q4 2025.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.